Cancer of the prostate: importance of androgen deprivation and radiotherapy
Rentsch, C.A.; Aebersold, D.M.; Merz, V.; Studer, U.E.
Revue Medicale Suisse 1(19): 1303-1306
2005
ISSN/ISBN: 1660-9379 PMID: 15962630 Document Number: 592817
Document emailed within 1 workday
Related Documents
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 809
Arai, G.; Okada, H. 2016: Androgen deprivation therapy for prostate cancer: adverse effects and their management Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 605-609
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257
Ying, J.; Yao, D.-H.; Ren, X.-M. 2003: Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy Zhonghua Nan Ke Xue 9(3): 191-192; 196
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)
Ziaran, S.; Goncalves, F.M.; Wendl, J.; Trebaticky, B.; Breza, J.S. 2009: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy Bratislavske Lekarske Listy 110(9): 559-562
Pickles, T.; Pollack, A. 2006: The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer Canadian Journal of Urology 13(Suppl 2): 68-71
Greco, C.; Castiglioni, S.; Fodor, A.; Mazzetta, C.; De Cobelli, O.; Orecchia, R. 2004: Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal radiotherapy of organ-confined prostate cancer: the experience of the European Institute of Oncology Tumori 90(6): 567-572
Blank, K.R.; Whittington, R.; Arjomandy, B.; Wein, A.J.; Broderick, G.; Staley, J.; Malkowicz, S.B. 1999: Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity Cancer Journal From Scientific American 5(6): 370-373
Soloway, M.S. 1990: The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy Progress in Clinical and Biological Research 350: 141-148
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Gao, J.; Isaacs, J.T. 1998: Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells Cancer Research 58(15): 3299-3306
Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G.; Isaacs, W.B.; Nassif, N. 1998: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells Cancer Research 58(23): 5310-5314
Mizokami, A.; Izumi, K.; Namiki, M. 2016: Role of adrenal androgen in prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 99-105
Roth, B.J. 1999: Androgen-independent prostate cancer: not so chemorefractory after all Seminars in Oncology 26(6 Suppl 18: 43-50